Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis
NCT ID: NCT04741087
Last Updated: 2022-09-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
22 participants
INTERVENTIONAL
2021-02-05
2022-04-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics
NCT02525523
Assessment of Patients With Acute Pouchitis Treated With Antibiotics
NCT05252273
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects
NCT01695876
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
NCT03110133
Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD
NCT03824795
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AMT-101 (Dose A)
Dose A: AMT-101 Tablet
AMT-101 (oral)-Dose A
AMT-101 is an orally administered biologic therapeutic, taken once daily.
AMT-101 (Dose B)
Dose B: AMT-101 Tablet
AMT-101 (oral)-Dose B
AMT-101 is an orally administered biologic therapeutic, taken once daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AMT-101 (oral)-Dose A
AMT-101 is an orally administered biologic therapeutic, taken once daily.
AMT-101 (oral)-Dose B
AMT-101 is an orally administered biologic therapeutic, taken once daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* History or current evidence of colonic or abdominal abnormalities.
* Previous exposure to AMT-101 or similar and known hypersensitivity to AMT-101 or its excipients.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Applied Molecular Transport
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Connecticut Clinical Research Institute
Bristol, Connecticut, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Chevy Chase Clinical Research
Chevy Chase, Maryland, United States
Mayo Clinic
Rochester, Minnesota, United States
Gastrointestinal Associates - Jackson
Flowood, Mississippi, United States
University of North Carolina GI
Chapel Hill, North Carolina, United States
Gastro One
Germantown, Tennessee, United States
Gastrointestinal Asssociates- GIA Clinical Trials, LLC
Knoxville, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Tyler Research Institute, LLC
Tyler, Texas, United States
University of Utah Health Sciences Center
Salt Lake City, Utah, United States
Washington Gastroenterology, Tacoma
Tacoma, Washington, United States
UZ Leuven - University Hospital Gasthuisberg
Leuven, , Belgium
Groupe santé CHC / Clinique du MontLégia, Liege
Liège, , Belgium
GI Research Institute
Vancouver, British Columbia, Canada
CHU de Rennes - Hopital de Pontchaillou
Rennes, , France
CHU Saint Etienne - Hopital Nord
Saint-Priest-en-Jarez, , France
CHU de Toulouse - Hôpital Rangueil
Toulouse, , France
CHRU Nancy - Hopital de Brabois
Vandœuvre-lès-Nancy, , France
Praxis fur Gastroenterologie am Bayerischen Platz
Berlin, , Germany
Klinik für Innere Medizin KIM IV
Jena, , Germany
UKSH Universitätsklinikum Schleswig-Holstein
Kiel, , Germany
University Hospital Tübingen
Tübingen, , Germany
Semmelweis Egyetem I. sz Belgyogyaszati Klinika
Budapest, , Hungary
Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar
Szeged, , Hungary
ETZ - Elisabeth
Tilburg, , Netherlands
Hospital Universitario y Politecnico La Fe de Valencia
Valencia, , Spain
Clarunis Bauchzentrum
Basel, , Switzerland
University Hospital of Zürich
Zurich, , Switzerland
MAC Clinical Research - Blackpool
Blackpool, Lancashire, United Kingdom
MAC Clinical Research - Liverpool
Prescot, Liverpool, United Kingdom
MAC Clinical Research - Cannock
Cannock, South Staffordshire, United Kingdom
MAC Clinical Research - Leeds
Leeds, West Yorkshire, United Kingdom
MAC Clinical Research - Manchester
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMT-101-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.